Seattle, WA. (PRWEB) May 27, 2016
NeuMedics Inc. is pleased to announce that CEO Iain Duncan has been invited to give a podium presentation at Life Science Innovation Northwest on June 2, 2016. The session begins at 1:10 PM and Iain will present the proof of concept data that demonstrates NeuMedics compound and propriety microemulsion can be successfully used as a topical agent and a treatment for ophthalmic complications of diabetes.
Mr. Duncan will also detail the results of a proof of principle study that was made possible through a grant from Washington State Life Science Discovery Fund.
“NM108 has a different mechanism of action than all of the anti-VEGF drugs on the market and currently in development,” says Duncan, “It targets the micro glia and short circuits the inflammation inside the eye that leads to the formation of VEGF. Our goal is to eliminate the need for intravitreal injection, the current standard of care for people who suffer from diabetic retinopathies.”
According to the U.S. Centers for Disease Control and Prevention, Diabetic Retinopathy is the leading cause of blindness in diabetics worldwide and The World Health Organization estimates 11% of the 347 million people suffering from diabetes also suffer from Diabetic Retinopathy. Intraocular injection of vascular endothelial growth factor (VEGF) inhibitors dominates the available therapies for the treatment of Diabetic Retinopathy, Diabetic Macular Edema, and Retinal Vein Occlusion. There is a significant need for effective and patient-friendly therapeutics for retinal diseases that address new cellular pathways, which can be regularly administered as an eye drop.
Event Information:
Life Science Innovation Northwest
When: June 1-2, 2016
Where: Washington State Convention Center
800 Convention Place
Seattle, WA.
http://www.lifesciencewa.org/?page=LSINW_16
About NeuMedics
NeuMedics is a specialty biopharmaceutical company based in Seattle that is focused on improving patients' lives by identifying and developing, novel therapeutics for the treatment of retinal diseases that can be safely and chronically administered as an eye drop.
For more information, please go to http://www.NeuMedics.com
